JPRN-jRCTs031210134
Completed
未知
Safety and pharmacokinetic study of a new PET probe [18F]FEDAC in healthy adults
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Tamura Kentaro
- Enrollment
- 10
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Healthy male subjects aged 20 or older and under 65 at the time of informed consent
- •2\. Subjects who provide written informed consent
- •3\. Subjects with BMI of less than 25
Exclusion Criteria
- •1\. Subjects who have severe or progressive complications.
- •2\. Subjects who have obvious abnormalities in physical and laboratory examinations after obtaining the informed consent
- •3\. Subjects who have past history of severe drug hypersensitivity
- •4\. Subjects with drug or alcohol addiction
- •5\. Subjects who smoke
- •6\. Subjects who have received medication or used vitamins, herbal medicines, or supplements within 14 days prior to their visit
- •7\. Subjects who are claustrophobic
- •8\. Subjects who have undergone an examination with radiation exposure for the purpose of medical treatment (X\-ray, CT, PET, DEXA, etc.) within the past 12 months, or for the purpose of research within the past 6 months. Chest X\-rays conducted as part of the annual medical check are excluded.
- •9\. Subjects who are considered to be inappropriate to participate in this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
First in patients of a New PET Probe FEDACMalignant tumors(solid tumors)JPRN-jRCTs031220192Tamura Kentaro30
Active, not recruiting
Not Applicable
A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced AdolescentsEUCTR2008-003917-29-GBGilead Sciences Incorporated24
Active, not recruiting
Phase 1
Study to evaluate product flow, breakdown and elimination from the body of a new contrast agent used in radiological examination and to evaluate its safety and efficacy in children from 2 to 17 years.EUCTR2018-001516-30-BGGUERBET60
Active, not recruiting
Phase 1
Study to evaluate product flow, breakdown and elimination from the body of a new contrast agent used in radiological examination and to evaluate its safety and efficacy in children from 2 to 17 years.Pediatric subjects from 2 to 17 years old scheduled to undergo routine gadolinium contrast enhanced Magnetic Resonance ImagingMedDRA version: 22.1Level: LLTClassification code 10029817Term: Nuclear magnetic resonance imaging brainSystem Organ Class: 100000004848MedDRA version: 22.1Level: LLTClassification code 10072232Term: Nuclear magnetic resonance imaging spinalSystem Organ Class: 100000004848Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2018-001516-30-PLGUERBET80
Active, not recruiting
Phase 1
Study to evaluate product flow, breakdown and elimination from the body of a new contrast agent used in radiological examination and to evaluate its safety and efficacy in children from 2 to 17 years.EUCTR2018-001516-30-SKGUERBET80